A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate (Q41180799)

27 September 2017

A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate (English)

1 reference

27 September 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Weiguang Zeng

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Amabel C L Tan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Kylie Horrocks

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

3 June 2015

1 reference

27 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

3526-3532

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26049002%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Traditional and new influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Cross-protective immunity to influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

A "universal" human influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

M2e-based universal influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Characterization of immunity induced by M2e of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Use of Fmoc-N-(2-hydroxy-4-methoxybenzyl)amino acids in peptide synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Recognition of lipopeptides by Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Intranasal Vaccination with a Lipopeptide Containing a Conformationally Constrained Conserved Minimal Peptide, a Universal T Cell Epitope, and a Self‐Adjuvanting Lipid Protects Mice from Group A Streptococcus Challenge and Reduces Throat Colonizati

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Studies on the usefulness of intranasal inactivated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Development of an M2e-specific enzyme-linked immunosorbent assay for differentiating infected from vaccinated animals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

Universal influenza A vaccine: optimization of M2-based constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

The immune geography of IgA induction and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053

The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.053